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The physiologic regulation of coronary blood flow ultimately involves the arterial vascular smooth musculature. Coronary vasoconstriction or vasodilation appropriately alters coronary resistance to blood flow in response to myocardial oxygen demands [ 1 ] . In this issue of the Journal of Intensive Care Medicine, Dr Conti describes the nonphysiologic exaggeration of coronary vasoconstriction of large epicardial conductance vessels, or coronary spasm, impairing coronary flow considerably and producing myocardial ischemia in the absence of any increases in the determinants of myocardial oxygen demand (i.e., heart rate, contractility, or left ventricular wall stress [pressure, volume] [2] ). Dr Conti and colleagues comprehensively discuss the definition and clinical features of coronary artery spasm and variant angina, detailing the use of various drug and revascularization therapies in the treatment of spasm.
Despite extensive research, the causes of coronary spasm have remained elusive. Moreover, exaggerated or inappropriate coronary vasoconstriction associated with atherosclerotic narrowings of the coronary lumen in recent years has changed the notion of &dquo;fixed&dquo; coronary obstructions and yielded a more dynamic concept of obstruction to blood flow [3] . For the clinician considering coronary spasm, two major aspects emerge as continuing problem areas. First, coronary spasm must be put in perspective as a phenomenon occurring over a clinical spectrum from marked epicardial vessel spasm producing ischemia in &dquo;normal&dquo; arteries to small degrees of coronary vasoconstriction superimposed on &dquo;fixed&dquo; atherosclerotic obstructions. Second, the optimal therapy for the patient with coronary spasm must be tailored to the degree of myocardial ischemia depending on the balance between pure spasm with normal coronary arteries and coronary vasomotion with severe atherosclerotic luminal narrowings. As previously described by Dr Conti and others [3] , coronary spasm or vasomotion superimposed on either &dquo;fixed&dquo; atherosclerotic coronary artery disease or radiographically normal coronary arteries produces a spectrum of clinical and pathophysiologic conditions of myocardial ischemia. Although dramatic in presentation, coronary artery spasm in patients without associated coro-_ nary artery disease occurs in only a few patients.
However, the effects of coronary spasm may be more commonly observed if coronary vasomotion-small changes, either vasoconstrictive or vasodilative, in caliber-are considered. Coronary vasomotion is clinically apparent most often in patients with severe (usually triple-vessel) atherosclerotic luminal narrowings and in whom any small change in coronary caliber is accompanied by a geometrically inverse change in resistance [4] . The pairing of vasomotion with reduced coronary lumen implicates coronary spasm as a common cophenomenon and possible etiologic factor in cases of unstable angina and myocardial infarction [5] .
Moreover, Epstein and others [3] noted that there are dynamic alterations of coronary flow that are related to the degree of stenosis, neurohumeral factors mediating epicardial vasoconstriction, and vasodilation in secondary resistance circuits. These dynamic as well as tonic or vasospastic mechanisms appear to contribute to or precipitate myocardial ischemia and must also be considered in patients with myocardial ischemia, even in the absence of classic findings of coronary artery spasm. Thus, some patients may have symptoms consistent with a mixed form of angina pectoris characterized by episodes of increased myocardial oxygen demands in conjunction with or independent of transient coronary constriction with impairment of oxygen supply [6] .
The treatment of patients with coronary spasm depends on the position in the clinical spectrum that they occupy: coronary spasm with minimal atherosclerotic obstructions, severe coronary narrowings with only small changes in vessel caliber, or somewhere in between. As Dr Conti emphasizes, ischemia resulting from reduced flow in patients with severely stenotic vessels may be due to transient occlusion by thrombi or platelet plugging.
Differentiation of spasm in this setting may be impossible but should remain a consideration among the therapeutic aims.
The most potent spasmolytic agents in clinical practice are the nitrates and calcium channel blockers. Nitrates alone may be sufficient to prevent or abolish coronary spasm, but most patients may have lasting benefit from calcium channel blockade alone or in combination with nitrates. Although not contraindicated, the use of beta adrenergicblocking drugs in patients with coronary spasm has been questioned [7, 8] and limited to patients with mixed anginal syndromes in whom benefit is achieved primarily through reduction in myocardial oxygen demand. Some investigators point out that calcium antagonists, such as diltiazem, reduce resting heart rate and systemic pressure and block coronary spasm; thus, they may be a preferred therapeutic choice for the patient with mixed angina. In patients with severe coronary narrowings and rest angina, antiplatelet agents, heparin sodium, and calcium antagonists are often a necessary addition to the standard agents used to reduce myocardial oxygen demand. Clinicians treating episodic myocardial ischemia should consider coronary spasm as a ubiquitous companion phenomenon and use the current pathophysiologic concepts discussed by Dr
